ClinConnect ClinConnect Logo
Search / Trial NCT06900803

Evaluating Dashboard-Integrated Pharmacist-Led Education on Improving Sacubitril/Valsartan Adherence in Heart Failure (PharmD ASSIST HFrEF)

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Mar 23, 2025

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

Heart Failure With Reduced Ejection Fraction Medication Adherence Dashboard Health Information Technology Patient Education Pharmacist Pragmatic Trial Randomized Controlled Trial Sacubitril/Valsartan Implementation

ClinConnect Summary

This clinical trial, called PharmD ASSIST HFrEF, is studying whether education led by pharmacists, using special interactive dashboards, can help patients with heart failure stick to their medication regimen, specifically the drug sacubitril/valsartan. The researchers want to see if this approach improves how well patients take their medicine compared to standard education without the dashboards. By comparing these two groups, the trial aims to find out if the pharmacist-led education can lead to better medication adherence and overall health outcomes for patients.

To qualify for this study, participants must be adults aged 20 or older who have been diagnosed with heart failure and are currently taking sacubitril/valsartan. They should be receiving care at the cardiology department of National Taiwan University Hospital. Those who join will complete questionnaires about their medication use and satisfaction with the care they receive, and they will attend educational sessions with pharmacists, either with or without the use of the dashboards. It’s important to note that individuals who have already attended the pharmacist-led heart failure clinic or are unable to participate fully in the study will not be eligible. The trial is not yet recruiting participants, but it promises to provide valuable insights into improving medication adherence for heart failure patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • adults aged 20 or older
  • a diagnosis of HFrEF, which is defined by a left ventricular ejection fraction of 40% or less
  • currently receiving sacubitril/valsartan at the time of recruitment
  • receiving care at the cardiology department or cardiology ward at National Taiwan University Hospital
  • referral from the clinicians at National Taiwan University Hospital
  • Exclusion Criteria:
  • unable or unwilling to provide informed consent, adhere to study protocols, or complete required questionnaires in person during three scheduled visits (i.e., 3, 6, 12 months after the baseline measurement)
  • having received care at the pharmacist-led HF clinic at National Taiwan University Hospital

About National Taiwan University Hospital

National Taiwan University Hospital (NTUH) is a leading medical institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a pioneer in medical education and patient care in Taiwan, NTUH integrates cutting-edge technology with comprehensive clinical expertise to facilitate groundbreaking studies across various medical fields. The hospital’s dedicated research team collaborates with local and international partners to enhance the understanding of diseases and improve treatment outcomes. By prioritizing patient safety and ethical standards, NTUH strives to contribute to the global medical community and foster advancements in healthcare practices.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported